PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 51,900 shares, a drop of 15.9% from the October 31st total of 61,700 shares. Based on an average daily volume of 34,700 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.7% of the shares of the company are short sold.
PharmaCyte Biotech Price Performance
NASDAQ PMCB opened at $1.71 on Friday. The business’s fifty day moving average is $1.77 and its 200-day moving average is $1.89. The stock has a market capitalization of $13.13 million, a price-to-earnings ratio of 2.61 and a beta of -0.20. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58.
PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) last announced its quarterly earnings data on Monday, September 16th. The company reported $0.14 EPS for the quarter.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Read More
- Five stocks we like better than PharmaCyte Biotech
- Where Do I Find 52-Week Highs and Lows?
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Penny Stocks Ready to Break Out in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
